This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yuan, Q.-a. Articles by Adams, G. P. Search for Related Content PubMed PubMed Citation Articles by Yuan, Q.-a. Articles by Adams, G. P.

Research Articles: Therapeutics

Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer

¹ Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania and ² Department of Cancer Immunology and AIDS, Dana-Farber Cancer Center, Harvard Medical School, Boston, Massachusetts

Requests for reprints: Gregory P. Adams, Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. Phone: 215-728-3890; Fax: 215-728-2741; E-mail: gp_adams{at}fccc.edu

The Müllerian inhibiting substance type II receptor (MISIIR) is involved in Müllerian duct regression as part of the development of the male reproductive system. In adult females, MISIIR is present on ovarian surface epithelium and is frequently expressed on human epithelial ovarian cancer cells. Müllerian inhibiting substance has been found to be capable of inhibiting the growth of primary human ovarian cancer cells derived from ascites and ovarian cancer cell lines. This suggested to us that MISIIR could be an attractive target for antibody-based tumor targeting and growth inhibition strategies. Here, we describe the production of recombinant human MISIIR extracellular domain-human immunoglobulin Fc domain fusion proteins and their use as targets for the selection of MISIIR-specific human single-chain variable fragments (scFv) molecules from a human nonimmune scFv phage display library. The binding kinetics of the resulting anti-MISIIR scFv clones were characterized and two were employed as the basis for the construction of bivalent scFv:Fc antibody-based molecules. Both bound specifically to human ovarian carcinoma cells in flow cytometry assays and cross-reacted with mouse MISIIR. These results indicate that antibody-based constructs may provide a highly specific means of targeting MISIIR on human ovarian carcinoma cells for the purpose of diagnosing and treating this disease. [Mol Cancer Ther 2006;5(8):2096–105]

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: Q-an Yuan and H.H. Simmons contributed equally to the work.

Received 3/ 1/06; revised 4/18/06; accepted 6/15/06.

This article has been cited by other articles:

				M. K. Robinson, C. Shaller, K. Garmestani, P. S. Plascjak, K. M. Hodge, Q.-A. Yuan, J. D. Marks, T. A. Waldmann, M. W. Brechbiel, and G. P. Adams Effective Treatment of Established Human Breast Tumor Xenografts in Immunodeficient Mice with a Single Dose of the {alpha}-Emitting Radioisotope Astatine-211 Conjugated to Anti-HER2/neu Diabodies Clin. Cancer Res., February 1, 2008; 14(3): 875 - 882. [Abstract] [Full Text] [PDF]